Needham Reiterates Buy on OrthoPediatrics, Maintains $42 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has reiterated a Buy rating on OrthoPediatrics (NASDAQ:KIDS) and maintained a price target of $42.
September 13, 2024 | 9:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson has reiterated a Buy rating on OrthoPediatrics and maintained a price target of $42, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $42 price target by a reputable analyst suggests positive sentiment and confidence in OrthoPediatrics' future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100